Latest News
Conference Coverage
ICIs improve pCR rates in early ER+/HER2– breast cancer
Nivolumab and pembrolizumab boosted pathologic complete response rates when added to neoadjuvant and adjuvant therapy in patients with high-risk...
Conference Coverage
Observation, not radiotherapy, after radical prostatectomy
The investigators observed no benefit to adjuvant radiotherapy after radical prostatectomy in patients with prostate cancer in the phase 3...
Conference Coverage
No benefit to adding ICI to chemo in triple-negative breast cancer: study
There were no differences in 5-year event-free survival among patients with TNBC who received neoadjuvant chemotherapy with or without...
Conference Coverage
Remote symptom monitoring in advanced cancer improves quality of life
Building on prior studies, a new trial shows that digital symptom monitoring during cancer treatment detects symptoms early, improves quality of...
Conference Coverage
Fasting during breast cancer chemo improves quality of life
Short-term fasting around the time of chemotherapy is a promising supportive therapy during breast cancer chemotherapy that may enhance quality of...
Conference Coverage
Does first-line pembrolizumab add-on improve PFS in high-risk cervical cancer?
An FDA decision is expected in January on pembrolizumab with concurrent chemoradiotherapy for the first-line treatment of locally advanced...
Conference Coverage
Adjuvant abemaciclib-ET combo shows long-term benefit in high-risk early breast cancer
Invasive disease–free and distant recurrence–free survival were better with the CDK4/6 inhibitor plus endocrine therapy than endocrine therapy...
Latest News
FDA proposes ban on hair straightener ingredients
The proposal specifies that formaldehyde would be banned, as well as other chemicals that release formaldehyde, such as methylene glycol.
Latest News
FDA approves nivolumab for resected stage IIB/C melanoma
Approval was based on findings from a phase 3 trial, which randomly assigned 790 patients to receive nivolumab or placebo by intravenous infusion...
Latest News
Prior authorization software: Saves time but hurdles remain
The automation works, but the software can be costly and may not work for all practices.
From the Journals
Doublet therapy ups survival in metastatic prostate cancer
“A clinically meaningful increase in long-term survival was observed in men diagnosed with de novo [metastatic castration-sensitive prostate...